Automated Breast Ultrasound Systems Market Size By Product, By End-use, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022

Description

List of Tables

The global automated breast ultrasound systems (ABUS) market is anticipated to register sizeable growth by 2030. The rising prevalence of breast cancer has dramatically fueled the need for advanced medical screening and diagnostic tools. Automated breast ultrasound systems (ABUS) can effectively address the limitations of existing breast cancer screening systems such as mammograms. It caters to challenges faced in identifying the presence of very small tumors that are often left undetected, especially in dense breast tissues.

Notable advancements in software technology will support the development of diagnostic imaging solutions for early cancer detection. For instance, in July 2021, cloud company Infor launched a new interoperability solution called FHIR Server catering to the healthcare sector by enhancing the efficiency of data analysis.

Various countries such as the U.S. are introducing favorable reimbursement policies for digital breast tomosynthesis and breast ultrasound. Such initiatives will empower women to undergo routine screening tests for breast cancer. Government support in managing healthcare expenses including public health insurance will drive patient interest in high-tech diagnostic technologies. Large organizations such as the American Cancer Society Cancer Action Network (ACSCAN) emphasize on the need for comprehensive coverage, enabling breast cancer screening for low-income groups.

The automated breast ultrasound systems (ABUS) industry is segregated into product, end-use, and region.

Based on the product, the market is bifurcated into automated breast ultrasound system (ABUS) and automated breast volume scanner (ABVS). Among these, ABUS product segment was valued at more than USD 950 million in 2021. Various concerns associated with existing breast cancer screening techniques such as discomfort or exposure to radiation are factors that will boost the popularity of ABUS.

Unlike mammograms, ABUS does not use compression, thus minimizing discomfort. The technology is safe for women of all age groups including younger females, pregnant women, and even lactating women. It can also be used to examine women with breast implants or post-operative scarring.

With respect to end-use, the industry is fragmented into specialty centers, hospitals, and diagnostic imaging centers. The ABUS market share from specialty centers is projected to exhibit over 14% CAGR from 2022-2030. Patients have a high preference for specialty hospitals as they provide access to substantial resources, extraordinary expertise, and favorable therapy programs. Studies have found that specialty centers have higher patient satisfaction as compared to general hospitals.

Europe automated breast ultrasound systems market size is poised to surpass USD 950 million by 2030. The surging prevalence of breast cancer due to unhealthy lifestyles and dietary habits along with genetic predisposition towards the disease will propel the demand for ABUS. The region has a solid footprint of industry leaders that are introducing novel products. For instance, in September 2020, French medical imaging expert SuperSonic Imagine launched its Hologic catalog in Austria, Germany, and Switzerland to enhance diagnostic reliability and ensure streamlined workflow.

Product Code: 728

Chapter 1 Methodology & Scope

1.1 Methodology
1.2 Base estimates and working
- 1.2.1 North America
- 1.2.2 Europe
- 1.2.3 Asia Pacific
- 1.2.4 Latin America
- 1.2.5 MEA
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 Automated breast ultrasound systems industry 360 degree synopsis, 2017 - 2030
- 2.1.1 Business trends
- 2.1.2 Product trends
- 2.1.3 End-use trends
- 2.1.4 Regional trends

Chapter 3 Automated Breast Ultrasound Systems Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030 (USD Million)
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Growing prevalence of breast cancer worldwide
  - 3.3.1.2 Rising technological advancements in automated breast ultrasound systems
  - 3.3.1.3 Limited capability of mammography in dense breast tissue patients
  - 3.3.1.4 Rising awareness and favorable government initiatives regarding breast cancer
  - 3.3.1.5 Increasing national breast screening programs across the globe
  - 3.3.1.6 Increased reimbursement for breast ultrasound and digital breast tomosynthesis in the U.S.
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 High cost of the automated breast ultrasound system devices
  - 3.3.2.2 Limited awareness of ABUS in developing countries
  - 3.3.2.3 Lack of skilled or trained personnel in emerging nations
3.4 Growth potential analysis
- 3.4.1 By product
- 3.4.2 By end-use
3.5 COVID- 19 impact analysis
3.6 Epidemiology analysis of breast cancer
3.7 Evolution of breast scanning tools
3.8 Regulatory landscape
- 3.8.1 U.S.
- 3.8.2 Europe
3.9 Product landscape
- 3.9.1 Pipeline analysis
- 3.9.2 FDA approved products
- 3.9.3 Digital breast tomosynthesis (DBT)
3.10 Porter's analysis
- 3.10.1 Bargaining power of suppliers
- 3.10.2 Bargaining power of buyers
- 3.10.3 Threat of new entrants
- 3.10.4 Threat of substitutes
- 3.10.5 Industry rivalry
3.11 Competitive landscape, 2021
- 3.11.1 Siemens AG
- 3.11.2 GE Healthcare
- 3.11.3 Koninklijke Philips N.V
- 3.11.4 Company matrix analysis, 2021
3.12 PESTEL analysis

Chapter 4 Automated Breast Ultrasound Systems Market, By Product

4.1 Key segment trends
4.2 Automated breast ultrasound system
- 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Automated breast volume scanner
- 4.3.1 Market size, by region, 2017 - 2030 (USD Million)
4.4 Others
- 4.4.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 5 Automated Breast Ultrasound Systems Market, By End-use

5.1 Key segment trends
5.2 Hospitals
- 5.2.1 Market size, by region, 2017 - 2030 (USD Million)
5.3 Diagnostic imaging centers
- 5.3.1 Market size, by region, 2017 - 2030 (USD Million)
5.4 Specialty centers
- 5.4.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 6 Automated Breast Ultrasound Systems Market, By Region

6.1 Key regional trends
6.2 North America
- 6.2.1 Market size, by country, 2017 - 2030 (USD Million)
- 6.2.2 Market size, by product, 2017 - 2030 (USD Million)
- 6.2.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.2.4 U.S.
  - 6.2.4.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.2.4.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.2.5 Canada
  - 6.2.5.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.2.5.2 Market size, by end-use, 2017 - 2030 (USD Million)
6.3 Europe
- 6.3.1 Market size, by country, 2017 - 2030 (USD Million)
- 6.3.2 Market size, by product, 2017 - 2030 (USD Million)
- 6.3.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.3.4 Germany
  - 6.3.4.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.3.4.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.3.5 UK
  - 6.3.5.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.3.5.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.3.6 France
  - 6.3.6.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.3.6.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.3.7 Spain
  - 6.3.7.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.3.7.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.3.8 Italy
  - 6.3.8.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.3.8.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.3.9 Russia
  - 6.3.9.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.3.9.2 Market size, by end-use, 2017 - 2030 (USD Million)
6.4 Asia Pacific
- 6.4.1 Market size, by country, 2017 - 2030 (USD Million)
- 6.4.2 Market size, by product, 2017 - 2030 (USD Million)
- 6.4.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.4.4 China
  - 6.4.4.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.4.4.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.4.5 Japan
  - 6.4.5.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.4.5.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.4.6 India
  - 6.4.6.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.4.6.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.4.7 Australia
  - 6.4.7.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.4.7.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.4.8 Thailand
  - 6.4.8.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.4.8.2 Market size, by end-use, 2017 - 2030 (USD Million)
6.5 Latin America
- 6.5.1 Market size, by country, 2017 - 2030 (USD Million)
- 6.5.2 Market size, by product, 2017 - 2030 (USD Million)
- 6.5.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.5.4 Brazil
  - 6.5.4.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.5.4.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.5.5 Argentina
  - 6.5.5.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.5.5.2 Market size, by end-use, 2017 - 2030 (USD Million)
6.6 Middle East & Africa
- 6.6.1 Market size, by country, 2017 - 2030 (USD Million)
- 6.6.2 Market size, by product, 2017 - 2030 (USD Million)
- 6.6.3 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.6.4 Saudi Arabia
  - 6.6.4.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.6.4.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.6.5 UAE
  - 6.6.5.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.6.5.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 6.6.6 South Africa
  - 6.6.6.1 Market size, by product, 2017 - 2030 (USD Million)
  - 6.6.6.2 Market size, by end-use, 2017 - 2030 (USD Million)

Chapter 7 Company Profiles

7.1 Competitive dashboard, 2021
7.2 CapeRay Medical
- 7.2.1 Business overview
- 7.2.2 Financial data
- 7.2.3 Product landscape
- 7.2.4 Strategic outlook
- 7.2.5 SWOT analysis
7.3 Delphinus Medical Technologies, Inc
- 7.3.1 Business overview
- 7.3.2 Financial data
- 7.3.3 Product landscape
- 7.3.4 Strategic outlook
- 7.3.5 SWOT analysis
7.4 GE Healthcare
- 7.4.1 Business overview
- 7.4.2 Financial data
- 7.4.3 Product landscape
- 7.4.4 Strategic outlook
- 7.4.5 SWOT analysis
7.5 Hitachi Ltd.
- 7.5.1 Business overview
- 7.5.2 Financial data
- 7.5.3 Product landscape
- 7.5.4 Strategic outlook
- 7.5.5 SWOT analysis
7.6 Koninklijke Philips N.V
- 7.6.1 Business overview
- 7.6.2 Financial data
- 7.6.3 Product landscape
- 7.6.4 Strategic outlook
- 7.6.5 SWOT analysis
7.7 Metritrack, Inc
- 7.7.1 Business overview
- 7.7.2 Financial data
- 7.7.3 Product landscape
- 7.7.4 Strategic outlook
- 7.7.5 SWOT analysis
7.8 QView Medical Inc.
- 7.8.1 Business overview
- 7.8.2 Financial data
- 7.8.3 Product landscape
- 7.8.4 Strategic outlook
- 7.8.5 SWOT analysis
7.9 Real Imaging
- 7.9.1 Business overview
- 7.9.2 Financial data
- 7.9.3 Product landscape
- 7.9.4 Strategic outlook
- 7.9.5 SWOT analysis
7.10 Seno Medical Instruments Inc.
- 7.10.1 Business overview
- 7.10.2 Financial data
- 7.10.3 Product landscape
- 7.10.4 Strategic outlook
- 7.10.5 SWOT analysis
7.11 Shantou Institute of Ultrasonic Instruments Co., Ltd (SIUI)
- 7.11.1 Business overview
- 7.11.2 Financial data
- 7.11.3 Product landscape
- 7.11.4 Strategic outlook
- 7.11.5 SWOT analysis
7.12 Siemens AG
- 7.12.1 Business overview
- 7.12.2 Financial data
- 7.12.3 Product landscape
- 7.12.4 Strategic outlook
- 7.12.5 SWOT analysis
7.13 SonoCine, Inc
- 7.13.1 Business overview
- 7.13.2 Financial data
- 7.13.3 Product landscape
- 7.13.4 Strategic outlook
- 7.13.5 SWOT analysis
7.14 Supersonic Imagine
- 7.14.1 Business overview
- 7.14.2 Financial data
- 7.14.3 Product landscape
- 7.14.4 Strategic outlook
- 7.14.5 SWOT analysis
7.15 Theraclion
- 7.15.1 Business overview
- 7.15.2 Financial data
- 7.15.3 Product landscape
- 7.15.4 Strategic outlook
- 7.15.5 SWOT analysis
7.16 CANON MEDICAL SYSTEMS CORPORATION
- 7.16.1 Business overview
- 7.16.2 Financial data
- 7.16.3 Product landscape
- 7.16.4 Strategic outlook
- 7.16.5 SWOT analysis
7.17 Volpara Solutions Limited
- 7.17.1 Business overview
- 7.17.2 Financial data
- 7.17.3 Product landscape
- 7.17.4 Strategic outlook
- 7.17.5 SWOT analysis